BMC Cancer

‘Targeted Therapy’ cross journal collection with BMC Medicine, guest edited by Prof. Min Li (University of Oklahoma Health Sciences Center) and Dr. Yanis Boumber.
 

'Microbiome and Cancer’ cross journal collection with Microbiome and BMC Microbiology, guest edited by Prof. Christopher Staley, Dr. Jacques Ravel and Dr. Sean Devlin. 

Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice

In this article Felici et al. established long-term circulating tumour cells cultures from metastatic Cutaneous Melanoma patients and explored the in vitro and in vivo properties in NOD-SCID mice, including their metastatic potential.

Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma

Wang et al., demonstrated the efficacy of nonviral mcDNA-mediated bispecific CAR T cells against CD133 and GPC3 double-positive HCC cell line in vitro and HCC xenograft mice in vivo.

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Fang et al. demonstrated that APG-2449 exerts potent and durable antitumor activity in human NSCLC and ovarian tumor models, carrying ALK fusion or secondary mutations, when administered alone or in combination with other therapies. 

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.